• Broad-Spectrum Efficacy
• Established Safety Record
• Well Tolerated

TOPAMAX®
(topiramate)

Your logical choice
### Multiple Mechanisms of Action

<table>
<thead>
<tr>
<th>TOPAMAX</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blocks non-NMDA subtype (AMPA/kainate) of glutamate receptor</td>
<td>✓</td>
</tr>
<tr>
<td>Enhances effect of GABA</td>
<td>✓</td>
</tr>
<tr>
<td>Blocks Na⁺ channels</td>
<td>✓</td>
</tr>
<tr>
<td>Activates K⁺ channel conductance</td>
<td>✓</td>
</tr>
<tr>
<td>Blocks Ca²⁺ channels</td>
<td>✓</td>
</tr>
<tr>
<td>Carbonic anhydrase inhibition</td>
<td>✓</td>
</tr>
</tbody>
</table>

- Multiple mechanisms of action may contribute to antiseizure efficacy

### Approved for a Broad Spectrum of Patients

**TOPAMAX** is indicated as adjunctive therapy for patients in a broad range of age categories

- Children as young as 2 years of age
- Adults
Documented Broad-Spectrum Efficacy

<table>
<thead>
<tr>
<th>FDA-Approved Indication—Adjunctive Therapy</th>
<th>Partial-Onset Seizures in Adults</th>
<th>Partial-Onset Seizures in Patients ≥2 Years of Age</th>
<th>Primary Generalized Tonic-Clonic Seizures in Adults</th>
<th>Primary Generalized Tonic-Clonic Seizures in Patients ≥2 Years of Age</th>
<th>Seizures of Lennox-Gastaut Syndrome in Children and in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOPAMAX</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>divalproex sodium</td>
<td>✓</td>
<td>✓*</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>oxcarbazepine</td>
<td>✓</td>
<td>✓†</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>lamotrigine</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>levetiracetam</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

- Some first-generation antiepileptic drugs are not included in this table. Additional indications are:
  - "Carbamazepine has been found useful in the management of psychomotor (temporal lobe) epilepsy and, as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication. As an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs."  
  - "Dilantin (phenytoin) is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures."  

* Patients ≥10 years of age.  
† Patients ≥4 years of age.  
* Indicated for generalized seizures of Lennox-Gastaut syndrome.  
† Dilantin is a registered trademark of Parke-Davis, a Warner-Lambert Division, a Pfizer Company.
Proven Efficacy Across Seizure Types in Adults and Children

Primary Generalized Tonic-Clonic Seizures

Partial-Onset Seizures

Partial-Onset Seizures in Adults

Partial-Onset Seizures in Children 2 to 16 Years of Age
Efficacy as Early as 2 Weeks°

- Therapeutic effect shown as early as 2 weeks after start of TOPAMAX treatment°
- TOPAMAX at 200 mg/day is effective as adjunctive therapy when added to enzyme-inducing AEDs in adults with refractory partial-onset seizures°

Please see pages 8 and 9 for additional efficacy data.
Established Safety Record

- 3 million patients treated
- Favorable pharmacokinetics
  - Linear dose-plasma concentration relationship
  - No autoinduction
- Minimal drug interactions
  - Low protein binding
  - Low potential for P450 enzyme induction
- No significant interaction between TOPAMAX and combination oral contraceptives at TOPAMAX doses up to 200 mg/day
- No black box warnings
- Not associated with drug-induced weight gain
- Not associated with unfavorable changes in lipids

*Containing norethindrone 1 mg and ethinyl estradiol 35 µg.

†Although there was a dose-dependent decrease in ethinyl estradiol exposure for doses between 200 to 600 mg/day, the clinical significance of the changes exerted is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX. Patients taking estrogen-containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.

Please see pages 10 and 11 for additional safety considerations.
Well Tolerated at 200 mg/day

Most Common Adverse Events

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=92)</th>
<th>TOPAMAX 200 mg/day (n=171)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somnolence</td>
<td>9</td>
<td>15</td>
</tr>
<tr>
<td>Anorexia</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Nervousness</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

Adverse events more frequent in TOPAMAX-treated patients with reported incidence >5%. Patients in these add-on trials were receiving 1 to 2 concomitant AEDs in addition to TOPAMAX or placebo.

Flexible Dosing

Commonly Used BID Titration Schedule for Adults

<table>
<thead>
<tr>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 3</th>
<th>Week 4</th>
<th>After Week 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>AM Dose</td>
<td></td>
<td></td>
<td></td>
<td>Increase in weekly increments of 25 to 50 mg/day to effect</td>
</tr>
<tr>
<td>PM Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Initiate therapy with a PM dose of 25 to 50 mg of TOPAMAX
- Recommended daily dose of TOPAMAX in adults is 200 to 400 mg/day in two divided doses
- In children (ages 2 to 16 years), the recommended daily dose is approximately 5 to 9 mg/kg/day in two divided doses
Proven Efficacy

Primary Generalized Tonic-Clonic Seizures in Adults and Children

- Placebo + Baseline AEDs (n=40)
- TOPAMAX + Baseline AEDs (n=30)

Measured Over 20 Weeks

- ≥25% Reduction (P=0.06): 45%
- ≥50% Reduction (P=0.001): 67%
- ≥75% Reduction (P=0.037): 56%
- 100% Reduction (P=0.23): 13%

Partial-Onset Seizures in Adults

- Placebo + Baseline AEDs (n=45)
- TOPAMAX + Baseline AEDs (n=45)

Measured Over 16 Weeks

- ≥25% Reduction (P=0.006): 38%
- ≥50% Reduction (P=0.001): 69%
- ≥75% Reduction (P=0.06): 44%
- 100% Reduction (P=0.18): 7%
Partial-Onset Seizures in Children 2 to 16 Years of Age

- Placebo + Baseline AEDs (n=45)
- TOPAMAX + Baseline AEDs (n=41)

<table>
<thead>
<tr>
<th>Reduction</th>
<th>Placebo</th>
<th>TOPAMAX</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥25% Reduction</td>
<td>40%</td>
<td>54%</td>
</tr>
<tr>
<td>(P=0.30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥50% Reduction</td>
<td>20%</td>
<td>39%</td>
</tr>
<tr>
<td>(P=0.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥75% Reduction</td>
<td>2%</td>
<td>17%</td>
</tr>
<tr>
<td>(P=0.02)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100% Reduction</td>
<td>0%</td>
<td>5%</td>
</tr>
<tr>
<td>(P=0.20)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Measured Over 16 Weeks

Drop Attacks Associated With Lennox-Gastaut Syndrome

- Placebo + Baseline AEDs (n=49)
- TOPAMAX + Baseline AEDs (n=46)

<table>
<thead>
<tr>
<th>Reduction</th>
<th>Placebo</th>
<th>TOPAMAX</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥25% Reduction</td>
<td>22%</td>
<td>43%</td>
</tr>
<tr>
<td>(P=0.017)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥50% Reduction</td>
<td>14%</td>
<td>28%</td>
</tr>
<tr>
<td>(P=0.07)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥75% Reduction</td>
<td>6%</td>
<td>17%</td>
</tr>
<tr>
<td>(P=0.085)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100% Reduction</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>(P=0.221)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Measured Over 11 Weeks

TOPAMAX
(topiramate)
Your logical choice
Additional Safety Considerations

"Even small gains in weight within the range of healthy weights can carry health risks..."\(^3\)

Weight Change Observations in Epilepsy Clinical Trials\(^8\)

<table>
<thead>
<tr>
<th>Baseline Body Weight (lbs)</th>
<th>Mean Body Weight Loss (% of Baseline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;132 (241)</td>
<td>-2.5%</td>
</tr>
<tr>
<td>132 to 175 (595)</td>
<td>-4.4%</td>
</tr>
<tr>
<td>176 to 220 (356)</td>
<td>-5.0%</td>
</tr>
<tr>
<td>&gt;220 (127)</td>
<td>-8.4%</td>
</tr>
</tbody>
</table>

- In double-blind studies among adults, less than 1% of patients treated with TOPAMAX discontinued due to weight loss\(^9\)
In adjunctive clinical trials with children:

- After 6 months, mean weight loss was 0.6% of baseline body weight in patients treated with TOPAMAX; mean weight in children treated with TOPAMAX returned to baseline levels by month 7.
- After 14 to 19 months, children treated with TOPAMAX had a net weight gain of 8.5% (6 lbs).
- No children permanently discontinued TOPAMAX due to weight loss.
• Broad-Spectrum Efficacy
  – Primary generalized tonic-clonic seizures
  – Partial-onset seizures
  – Seizure types associated with Lennox-Gastaut syndrome

• Established Safety Record

• Well Tolerated

Indicated as adjunctive therapy for patients ≥2 years of age with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

In combination with other traditional antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were somnolence, dizziness, ataxia, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, and diplopia; and in children (5 to 9 mg/kg/day), somnolence, anorexia, fatigue, nervousness, difficulty with concentration/attention, weight decrease, aggressive reaction, and memory difficulty.

Serious as well as minor side effects have been reported with the use of TOPAMAX. Please see full Prescribing Information.


For representatives' use only. Not to be left with physician. Please provide full Prescribing Information.
TOPAMAX Case Study: Fourth in a Series

“She’s really a smart kid. But she can be out of it for a whole day or more when she’s had a couple of spells. Her grandma’s always telling me the pills are the problem...but they’re not if they stop her spells. Brianna was doing great until this last grading period when the seizures came back big time.”  

—Brianna’s mother

Brianna T.

Patient Profile
- 7-year-old 2nd grader who has achieved age-appropriate milestones
- Normal to above normal intelligence, but quickly bored in class and needs extra tasks and projects
- Height/weight: 65th/85th percentiles
- Epilepsy diagnosed at age 3 years (meningitis at age 6 months; febrile seizures until 20 months of age)

Epilepsy Treatment History
- Phenobarbital controlled seizures, but carbamazepine substituted due to severe irritability and behavior problems (biting, scratching)
- Carbamazepine maintained (blood level, 8 mcg/mL) with only occasional seizures (a day or two with a small flurry of 2 to 3 complex partial seizures every 2 to 3 months) from age 3½ to 5 years; higher blood levels caused too much sedation and slowing
- No seizures for 26 months on carbamazepine (doses adjusted to maintain blood level)

Concomitant Drug Therapy
- None reported

Presenting Complaint
After no seizures for more than 2 years, Brianna’s seizures reemerged 6 months ago, initially mirroring the earlier pattern. Since then, the pattern has changed; seizures have become longer in duration (up to 2 minutes), with longer recovery, and more frequent. Several episodes in the past 6 weeks suggest the presence of auras (“stinks like tar”). Three weeks ago, Brianna had her first episode in which a seizure generalized to a convulsion.

Since the reemergence of seizures, attempts to increase carbamazepine blood levels have not controlled seizures.

Clinical Dilemma
- Treatment failure with carbamazepine due to poor seizure control
TOPAMAX... The Next Step for Effective Seizure Control

**Reliable seizure control**
- Broad-spectrum efficacy
  - Partial-onset seizures
  - Primary generalized tonic-clonic seizures
  - Seizures of Lennox-Gastaut syndrome
- Clinically significant therapeutic effect
  - ≥50% seizure reduction in 39% of children (2 to 16 years of age) with partial-onset seizures receiving a median average dosage of 6 mg/kg/day of TOPAMAX therapy
- Multiple mechanisms of action may contribute to antiseizure efficacy

**Established safety record**
- 3 million patients treated
- Favorable pharmacokinetics
  - Linear dose-plasma concentration relationship
  - No autoinduction
- Minimal drug interactions
  - Low protein binding
  - Low potential for P450 enzyme induction
- No black box warnings
- Not associated with drug-induced weight gain

Indicated as adjunctive therapy for patients ≥2 years of age with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

In combination with other traditional antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were somnolence, dizziness, ataxia, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, and diplopia; and in children (5 to 9 mg/kg/day), somnolence, anorexia, fatigue, nervousness, difficulty with concentration/attention, weight decrease, aggressive reaction, and memory difficulty. Serious as well as minor side effects have been reported with the use of TOPAMAX. Please see full Prescribing Information.

**References:**

TOPAMAX® (topiramate)
Your logical choice

Please see accompanying full Prescribing Information. © OMP 2004 02T113 5/04
TOPAMAX Case Study: Third in a Series

"I've accepted that I'm going to need pills for the rest of my life if I don't want seizures. And I don't want...can't afford...any more seizures. Especially not when we're on the verge of making a major breakthrough with my robotic leg design."

Narish S.

Patient Profile
- 28-year-old biomedical engineer
- Identified as having borderline elevated LDL
- Epilepsy diagnosed 24 months ago after generalized tonic-clonic seizure without any clear provocative factor (sleep deprivation or alcohol); EEG showed asynchronous epileptiform pattern
- Twin brother recently diagnosed with epilepsy
- Smoker: 1 to 1½ packs per day

Epilepsy Treatment History
- Phenytoin started by the emergency department physician was continued when likelihood of seizure recurrence was discussed with Narish
- Carbamazepine added 9 months later, after 3 generalized tonic-clonic seizures occurred within an 8-week period (2 seizures possibly related to sleep deprivation)
- Maintained on 400 mg/day phenytoin and 1000 mg/day carbamazepine for the past 9 months
- Attempt at withdrawing phenytoin associated with a breakthrough seizure

Concomitant Drug Therapy
- None reported although primary care physician may start lipid-lowering drug therapy at next visit if LDL is still elevated

Presenting Complaint
Until 6 weeks ago, Narish had been seizure-free for 11 months. Narish has had 2 generalized tonic-clonic seizures, which he denies were triggered by lack of sleep or alcohol. Although he understands that sleep deprivation can trigger his seizures, it is occasionally unavoidable because of his job. One seizure occurred at work. His design team was previously unaware of his epilepsy. He cannot tolerate a higher phenytoin dose (severe ataxia) or a higher carbamazepine dose (dizziness).

Clinical Dilemma
- Treatment failure with phenytoin-carbamazepine combination due to poor seizure control
TOPAMAX... The Next Step for Effective Seizure Control

Reliable seizure control

- Broad-spectrum efficacy
  - Partial-onset seizures
  - Primary generalized tonic-clonic seizures
  - Seizures of Lennox-Gastaut syndrome
- Clinically significant therapeutic effect at doses as low as 200 mg/day\(^1\,\,2\)
  - \(\geq50\%\) seizure reduction in 45% of adults with partial-onset seizures receiving TOPAMAX 200 mg/day as add-on therapy\(^1\)
  - \(\geq50\%\) seizure reduction in 56% of adults and children with primary generalized tonic-clonic seizures receiving TOPAMAX as add-on therapy\(^2\)
- Early onset of therapeutic effect\(^1\)
  - Significant seizure reduction within 2 weeks at 100 mg/day\(^1\)
- Multiple mechanisms of action may contribute to antiseizure efficacy

Established safety record

- 3 million patients treated\(^3\)
- Favorable pharmacokinetics
  - Linear dose-plasma concentration relationship
  - No autoinduction
- Minimal drug interactions
  - Low protein binding
  - Low potential for P450 enzyme induction\(^4\)
- No black box warnings
- Not associated with drug-induced weight gain
- No significant potential for hyponatremia
- Not associated with unfavorable changes in lipids

Indicated as adjunctive therapy for patients \(\geq2\) years of age with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

In combination with other traditional antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were somnolence, dizziness, ataxia, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, and diplopia; and in children (5 to 9 mg/kg/day), somnolence, anorexia, fatigue, nervousness, difficulty with concentration/attention, weight decrease, aggressive reaction, and memory difficulty.

Serious as well as minor side effects have been reported with the use of TOPAMAX. Please see full Prescribing Information.